The group is currently focusing on putting into practice ALK translocation, studying how effective PI3K/mTOR inhibitors are in patients with EGFR-TKI-resistant lung cancer, and studying how effective PARP inhibitors are in lung cancer.

They are analysing the epidemiological and clinical characteristics of women diagnosed with lung cancer. They are committed to reinforcing a multidisciplinary approach to provide the best care for patients, and are proactive in the fight against smoking.

Visit the research group’s page

Centres
General Hospital
Vall d'Hebron Institute of Oncology
Serveis
Medical Oncology
Ponderació
9
Recerca
Grup de tumors toràcics
Enllaç
https://vhio.net/pf/thoracic-tumors-head-and-neck-cancer-group/

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.